Pharmacological Profile of the Chemically Synthesized Antithrombin III Binding Fragment of Heparin (Pentasaccharide) in Rats

Summary

The antithrombotic and haemostatic effects of a pentasaccharide, the chemically synthesized antithrombin III (AT-III) binding fragment of heparin (PENTA), were investigated in rats in comparison with heparin. PENTA showed a dose-dependent antithrombotic effect in three thrombosis models in which thrombus formation was induced by different triggers. PENTA was consistently less potent than heparin in these models if doses were expressed in anti-Xa U/kg but PENTA showed more or less the same potency as heparin if doses were expressed in mg/kg. The antithrombotic effect of PENTA was strongly related to its anti-Xa activity as judged from its antithrombotic potency in the various models and from the time courses of both activities. PENTA caused a dose-dependent increase in blood loss in a bleeding model but the dose response curve was rather flat; the effect of PENTA on blood loss was small compared to that of heparin. The duration of action of PENTA as measured by the plasma anti-Xa levels was long compared to that of heparin and the duration of the antithrombotic effect was that expected on the basis of the plasma anti-Xa levels.

Finally, PENTA showed comparable antithrombotic activity after s.c. and i.v. administration, as expected because of the approximately 100% bioavailability of the anti-Xa activity after s.c. administration.

• References

• 1 Gallus AS, Hirsh J, Tuttle RJ, Trebilcock R, O’Brien SE, Carroll J, Minden JH, Hudecki SM. Small subcutaneous doses of heparin in the prevention of venous thrombosis. N Engl J Med 1973; 288: 545-551
• 2 Gallus AS, Hirsh J. Prevention of venous thrombo-embolism. Sem Thromb Hemostas 1976; 2: 232-290
• 3 Hirsh J. Treatment of venous thrombosis with heparin. In Heparin: chemistry and clinical usage. Kakkar VV, Thomas JP. eds Academic Press; London: 1976: 175-188
• 4 Hirsh J. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding. Haemostasis 1986; 16: 82-86
• 5 Rosenberg RD. The heparin-antithrombin system. In Hemostasis and Thrombosis. Colman RW, Hirsh J, Harder VS, Salzman EW. eds Lippincott JP. Philadelphia; PA: 1982: 962-985
• 6 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fragments on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 7 Holmer E, Lindahl U, Bäckström G, Thunberg L, Sandberg H, Söderström G, Andersson L-O. Anticoagulant activities and effects on platelets of a heparin fragment with high affintiy for antithrombin. Thromb Res 1980; 18: 861-869
• 8 Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfragmentated heparin. Thromb Haemostas 1986 56. 243-246
• 9 Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemostas 1988; 59: 216-220
• 10 Turpie AG G, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 11 Kakkar VV, Murray WJ G. Efficacy and safety of low-molecularweight heparin (CY 216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
• 12 Juhan-Vague I, Elias A, Aillaud MF, Alessi MC, Bouvier JL, Lecorf G, Valadier J, Roul C, Serradimigni A. Treatment of deep vein thrombosis with a very low molecular weight heparin (CY 222- Choay): thrombolysis and plasma fibrinolytic parameters. Fibrinolysis 1988; 2: 25-29
• 13 Cade JF, Wood M, Magnani HM, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep vein thrombosis. Thromb Res 1987; 45: 497-503
• 14 Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M. Double-blind randomized trial of Org 10172 low-molecular-weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; I: 523-526
• 15 Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-649
• 16 Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410
• 17 Sinay P, Jacquinet JC, Petitou M, Duchaussoy P, Lederman I, Choay J, Torri G. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res 1984; 132: C5-9
• 18 Van Boeckel CA A, Beetz T, Vos JN, de Jong AJ M, van Aelst SF, van der Bosch RH, Mertens JM R, van der Vlugt FA. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem 1985; 4: 293-321
• 19 Ichikawa Y, Monden R, Kuzuhara H. Synthesis of a heparin pentasaccharide fragment with a high affinity for antithrombin III employing cellobiose as a key starting material. Tetrahedon Lett 1986; 27: 611-614
• 20 Walenga JM, Fareed J. Preliminary biochemical and pharmacological studies on a chemically synthetized pentasaccharide. Sem Thromb Haemostas 1985; 11: 89-99
• 21 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
• 22 Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33
• 23 Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemostas 1989; 61: 204-207
• 24 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified anti-thrombin III. Thromb Res 1977 10. 399-410
• 25 Vogel GM T, Meuleman DG, Bourgondiën FG M, Hobbelen PM J. Comparison of two experimental thrombosis models in rats. Effects of four glycosaminoglycans. Thromb Res 1989 54. 399-410
• 26 Sheiner LB. ELSFIT (updated version 3.1) a program for the extended least squares fit in individual pharmacokinetic data. Users manual Technical Report of the Div. of Clinical Pharmacology of the. University of California; San Francisco, CA: 01/1983
• 27 Bowman WC, Rand MJ. Textbook of Pharmacology, paragraph 41.37. Blackwell Scientific Publications; Oxford: 1980
• 28 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 29 Hobbelen PM J, Vogel GM T, Meuleman DG. Continuous monitoring of thrombus formation in an arteriovenous shunt with the AIMS-system; effects of heparin, Org 10172 and the ‘natural’ pentasaccharide. Thromb Haemostas 1989; 62: 120
• 30 Pieters J. The mechanism of action of heparin in purified systems and in plasma. Thesis, State University Limburg, Maastricht 1989
• 31 Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemostas 1989; 61: 397-401
• 32 Hobbelen PM J, Vogel GM T, Meuleman DG. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res 1987; 48: 549-558
• 33 Bârzu T, Van Rijn JL M L, Petitou M, Molho P, Tobelem G, Caen JP. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986 238. 847-854